105
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

, , , , , & show all
Pages 659-672 | Published online: 08 Nov 2019

Figures & data

Figure 1 Model structure.

Abbreviations: w/o, without; w/, with; AE, adverse event; UC, urothelial cancer.
Figure 1 Model structure.

Table 1 Market Share With And Without Uptake Of Avelumab As 2L Therapy

Table 7 Results Of Sensitivity Analyses – Budget Impact Over 3-Year Time Horizon

Table 2 Dosing, Duration, Drug And Administration Costs

Table 3 Percentage Of Patients Experiencing Grade ≥3 Adverse Events And Total Adverse Event Costs

Table 4 Healthcare Resource Costs Of Adverse Event Management

Table 5 Disease Management Costs

Figure 2 Budget impact of avelumab in the treatment of locally advanced or mUC (A) Commercial perspective and (B) Medicare perspective (US$).

Abbreviation: UC, urothelial carcinoma.
Figure 2 Budget impact of avelumab in the treatment of locally advanced or mUC (A) Commercial perspective and (B) Medicare perspective (US$).

Table 6 Budget Impact Over 3-Year Time Horizon